Preliminary evidence indicates that CPT1A may be a potential biomarker for chemotherapy resistance in colorectal cancer and that targeted modulation of mtDNA copy number may represent an effective strategy to reverse such resistance. This evidence concerns the gene CPT1A and colorectal cancer.